Kane Biotech (TSX-V:KNE, OTCQB:KNBIF) President & CEO Marc Edwards joins Natalie Stoberman from the Proactive newsroom to share more details behind the first distribution agreement for its coactiv+ Antimicrobial Hydrogel.
Edwards says Kane Biotech the agreement with Salud Pharma is a significant milestone to secure global partners and bring its technologies to the wound care and surgical markets.
The coactiv+ Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+ antibiofilm technology and PHMB in a thermo-reversible gel. The combination of these three components provides for a moist environment best suited for wound healing, with superior anti-microbial activity in an easy-to-use thermo-reversible gelling system that is optimized for sensitive wounds.